Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index; 10 of the 16 sources its claims cite were checked for support.
Abstract
Even though highly active anti-retroviral therapy is able to keep HIV-1 replication under control, the virus can lie in a dormant state within the host genome, known as a latent reservoir, and poses a threat to re-emerge at any time. However, novel technologies aimed at disrupting HIV-1 provirus may be capable of eradicating viral genomes from infected individuals. In this study, we showed the potential of the CRISPR/Cas9 system to edit the HIV-1 genome and block its expression. When LTR-targeting CRISPR/Cas9 components were transfected into HIV-1 LTR expression-dormant and -inducible T cells, a significant loss of LTR-driven expression was observed after stimulation. Sequence analysis confirmed that this CRISPR/Cas9 system efficiently cleaved and mutated LTR target sites. More importantly, this system was also able to remove internal viral genes from the host cell chromosome. Our results suggest that the CRISPR/Cas9 system may be a useful tool for curing HIV-1 infection.
Overview
CoChat Summary
TL;DR
The study shows that CRISPR/Cas9 targeting the HIV-1 LTR can disrupt proviral expression and excise integrated provirus in cell models. T5 gRNA targeting the TAR region was more effective than T6 targeting NF-κB, and repeated transfection improved suppression and excision.
Key findings
- In LTIG-transduced 293T cells, T5 gRNA reduced GFP-positive cells from 45.6% to 20.0% (p = 0.0003); triple transfection reduced GFP-positive cells from 40.8% to 2.1% (p = 0.0001).
- Sequence analysis found mutations in 18 of 22 HIV DNA clones, with 1–31-bp deletions from the putative cleavage site; two clones had deletion plus insertion mutations, consistent with NHEJ repair.
- In latent Jurkat clones c5 and c19, T5 reduced TNF-α-induced GFP-positive cells from 92.56% to 68.78% and from 98.48% to 66.95%, respectively; after three transfections in c19, reactivation fell from 97.8% to 35.5% (p = 0.00002).
- qPCR showed that on average 31.8% of provirus was excised after three transfections, and PCR detected a 1,067-bp footprint consistent with provirus excision leaving one LTR.
Methods
- Designed gRNA expression vectors targeting HIV-1 LTR: T5 against the TAR sequence in the R region and T6 against the NF-κB binding sequence in U3, co-transfected with human codon-optimized Cas9.
- Used HIV-1 provirus-integrated human cells: LTIG vector-transduced 293T and HeLa cells, plus Jurkat clones c5 and c19 that mimic HIV latency and were reactivated with TNF-α or 5-Aza-dC/TSA.
- Assessed GFP expression by flow cytometry, mutations by cloning and sequencing, proviral DNA amount by qPCR, and integration/excision by inverse PCR and flanking PCR; statistical analysis used Student’s t test.
Limitations
- The paper states that genome-editing and/or proviral excision efficiency should be quantified in HIV-infected primary cells, including latently infected CD4+ quiescent T cells.
- The paper states that an efficient delivery system must be developed and that possible off-target effects remain a concern for all genome-editing strategies.
- Evident from the text: most experiments use cell lines and engineered HIV vectors rather than primary patient cells; HeLa responses were modest, attributed to lower transfection efficiency and lower GFP expression; T6 was weaker because the 3′ NF-κB site may remain functional; and target-site mutations could allow some provirus to escape editing.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
10 Valid · 1 Not valid · 6 Not checked · 31 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“While highly active anti-retroviral therapy (HARRT) has dramatically decreased mortality from HIV-1 infection, there is currently no effective strategy to target the latent form of HIV-1 proviruses 5 .”
What the sources say
- Partly supportedcites [5] Eisele, E. & Siliciano, R. F. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 37, 377–388 (2012). sourceExperimental — accuracy not yet measured
The Introduction describes the latent reservoir as a major barrier to HIV-1 eradication. In “The latent reservoir in resting CD4+ T cells,” the paper says reactivation alone may not purge that reservoir, but it also reports that SAHA can perturb it in vivo. Thus, the paper supports the lack of an established strategy to eliminate latent infection, not the categorical claim that no strategy effectively targets it. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Fortunately, the CRISPR/Cas9 system has the advantage in size compared with TALENs 22 .”
What the sources say
- Partly supportedcites [22] Gaj, T., Gersbach, C. A. & Barbas, C. F. 3rd. ZFN, TALEN and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. (2013). sourceExperimental — accuracy not yet measured
The Future directions section says the large size of TALENs may limit delivery by size-restricted vectors. It does not compare TALEN size with CRISPR/Cas9 size, so it supports the TALEN size concern but not the claimed comparative advantage. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Triple TF resulted in a significant decrease in the mean percentage of GFP positive cells from 40.8% to 2.1% ( p = 0.0001) was observed.”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this study, we successfully disrupted the expression of HIV-1 provirus utilizing the CRISPR/Cas9 system ( Fig. 1 ).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A similar reduction in GFP expression was observed in c5 and c19 cells transfected with the T5 CRISPR/Cas9 system after 5-Aza-dC/TSA treatment ( Fig. 3A and B ).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
23 more claims
Create a free account to see all 48 claims and every source verdict.
- Probably not a substantial claim. 8
- It may state two separate claims as one. 14
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ebina et al. (2013) used calcium phosphate transfection to deliver plasmid DNA encoding Cas9 and sgRNA into latent HIV-1-infected human 293 T cells.”
From Delivering CRISPR: a review of the challenges and approaches (2018) · cites this paper as Ebina et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“various gene editing technologies have recently been shown to remove the proviral HIV-1 DNA from the host cell genome by targeting its highly conserved 5′ and 3′ long terminal repeats (LTRs)”
From RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection (2014) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“With the appropriate guide RNA, the Cas9 enzyme can recognize and cleave virtually any viral genome (29).”
From RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection (2014) · cites this paper as [29]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Off-target effects refer to the possibility that the CRISPR/Cas9 system may cut DNA at a non-specific location other than the target DNA, resulting in unwanted gene mutations or interference with normal gene function [10].”
From A Review of Research on CRISPR/Cas9 Gene Editing Technology in Disease Treatment (2024) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“However, this proof of concept is certainly applicable to any other cell type, including T-lymphoid cells (Fig. S6) (12,13), astrocytes, and neural stem cells”
From RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection (2014) · cites this paper as [12]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering
Gaj, T., Gersbach, C. A., & Barbas, C. F. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2013.04.004 · Cited by 3,820
Gasiunas, G., Barrangou, R., Horvath, P., & Siksnys, V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208507109 · Cited by 2,769
Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease
Cho, S. W., Kim, S., Kim, J. M., & Kim, J.-S. (2013) · Nature Biotechnology · doi:10.1038/nbt.2507 · Cited by 1,863
RNA-guided genetic silencing systems in bacteria and archaea
Wiedenheft, B., Sternberg, S. H., & Doudna, J. A. (2012) · Nature · doi:10.1038/nature10886 · Cited by 1,851
Highly efficient endogenous human gene correction using designed zinc-finger nucleases
Urnov, F. D., Miller, J. C., Lee, Y.-L., Beausejour, C. M., Rock, J. M., Augustus, S., Jamieson, A. C., Porteus, M. H., Gregory, P. D., & Holmes, M. C. (2005) · Nature · doi:10.1038/nature03556 · Cited by 1,641
Makarova, K. S., Grishin, N. V., Shabalina, S. A., Wolf, Y. I., & Koonin, E. V. (2006) · Biology Direct · doi:10.1186/1745-6150-1-7 · Cited by 1,199
Development of a self-inactivating lentivirus vector
Miyoshi, H., Blömer, U., Takahashi, M., Gage, F. H., & Verma, I. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.10.8150-8157.1998 · Cited by 1,196
HIV reproducibly establishes a latent infection after acute infection of T cells in vitro
Jordan, A., Bisgrove, D., & Verdin, E. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg188 · Cited by 914
Cited by
Items 501–562 of 562
[Use of a new peroral anticoryza drug. Experience in the industrial medical practice].
Schäfer, G. (1971) · PubMed
Novel technologies and their applications in biotechnology
Deeni, Y., Beccari, T., Dündar, M., Gartland, J. S., Maffia, M., Viola-Magni, M., & Gartland, K. M. A. (2014) · ResearchOnline
Milne, S. (2015) · OhioLink ETD Center (Ohio Library and Information Network)
CRISPR genome editing: A general view
Kumar, R. M. R. (2017) · Journal of Genetic Medicine and Gene Therapy · doi:10.29328/journal.jgmgt.1001001
“, reported the use of this technology in eradicating HIV viral genomes from infected individuals by genome editing of HIV-1 virus [3].”
MethodSherbeny, M., Abdalla, H., AbdElHady, E., Elbastawesy, S., HAMPSON, I. N., & Ali, M. (2017) · International Journal of Advanced Research · doi:10.21474/ijar01/5197
“…the cas9 to the target gene by base pairing, resulting in site specific DNA double –strand breaks(DSBs) which subsequently repaired by non homologous end joining (NHEJ) pathway or homology directed repair (HDR) pathway result in disruption of the target gene (Ebina et al., 2013, Cong et al., 2013).”
BackgroundOptimizing Crispr Cas9 Genome Editing System:A Review
Budhthoki, M. B., Sharma, P. C., Khan, S. D., Singh, S., Chao, F., & Yong, L. (2017) · INTERNATIONAL JOURNAL OF ENDORSING HEALTH SCIENCE RESEARCH (IJEHSR) · doi:10.29052/ijehsr.v5.i1.2017.48-62
Genome Editing During Development Using the CRISPR-Cas Technology
Arzate‐Mejía, R. G., Licona-Limón, P., & Targa, F. R. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7714-7_16 · Cited by 1
Unique natural and adaptive response mechanisms to control and eradicate HIV infection
Amsterdam, D. (2018) · AIMS Allergy and Immunology · doi:10.3934/allergy.2018.3.113
“In other studies, investigators attempted to eliminate HIV provirus from T cells by targeting the LTR region of the provirus as HIV-1 gene expression is regulated by the LTR promoter [73,74].”
Howaidi, J., Howaidi, A., & Howaidi, F. (2019) · Journal of Nature and Science of Medicine · doi:10.4103/jnsm.jnsm_52_18
Latency reversing agents affect HIV RNA splicing
Mota, T. M. (2017) · Minerva Access (University of Melbourne)
The effects of 7β-OH Epiandrosterone on Cytokine production by human immune cells
Almartagi, M. A. A. (2018) · STAX · doi:10.48730/tq8j-c084
Chávez, L., Reddy, N. R., Raymond, K. A., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-45582/v1
Madariaga, I., Duque-Restrepo, J. C., Ayala, P., & García‐Robles, R. (2020) · IATREIA · doi:10.17533/udea.iatreia.56 · Cited by 1
Lai, M., Maori, E., Quaranta, P., Matteoli, G., Maggi, F., Sgarbanti, M., Crucitta, S., Pacini, S., Turriziani, O., Freer, G., et al. (2020) · SSRN Electronic Journal · doi:10.1101/2020.11.16.384180
Sintya, E., Wedari, N. L. P. H., Pranata, I. W. A., & Budayanti, N. N. S. (2021) · Journal of Clinical Microbiology and Infectious Diseases · doi:10.51559/jcmid.v1i1.4 · Cited by 2
Ortiz-Arrazola, O. J., & Rincón-Castro, M. C. D. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.01.454629
“The CRISPR/Cas9 system has recently been used for genetic modification in some large genome viruses (Ebina et al., 2013; King & Munger, 2019).”
MethodJain, D. K., Gupta, Y. K., Sinha, P., Gupta, S., Vijayvergia, V., & Batra, S. (2021) · Journal of Evidence Based Medicine and Healthcare · doi:10.18410/jebmh/2021/436
Current Status of Approaches to Eradicate HIV Infection
Wolkenberg, S. E., Marrouni, A. E., Converso, A., Tellers, D. M., Barnard, R. J. O., & Diamond, T. L. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc281
CRISPR-Cas13 and its Applications in Human Therapeutics
Rao, K. (2021) · Journal of High School Science · doi:10.64336/001c.30072 · Cited by 1
Seraj, Z. I., & Hque, S. (2022) · Journal of Bangladesh Academy of Sciences · doi:10.3329/jbas.v45i2.57208 · Cited by 2
“…technology to target HIV-1 LTR, they observed a significant loss of LTRdriven expression of this virus, and also this system was being able to remove embedded viral genes from chromosome indicating the significance of CRISPR/Cas technology in the treatment of deadly AIDS (Ebina et al., 2013).”
BackgroundInfluentialLundstrom, K. H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818731-9.00137-3
Genome Editing in Cellular Disease Models
Theurey, P., Thiam, K., Chérifi, Y., Fraichard, A., & Rezza, A. (2022) · Wiley eBooks · doi:10.1002/9781119671404.ch6
Regulación de Cas9 por las proteínas virales Tat y Rev para la inactivación del VIH-1
Vergara‐Mendoza, M. (2020) · doi:10.24275/uami.5d86p046q
Concept of CRISPR-CAS9 Technology and Its Application in Crop Improvement Systems
Kaur, R., Bharti, U., & Tanda, A. S. (2022) · Springer eBooks · doi:10.1007/978-3-030-92152-1_12 · Cited by 1
ERA DA EDIÇÃO GÊNICA: APLICAÇÕES E FUTURO
Petry, B., & Moreira, G. C. M. (2022) · Instituto de Inteligência em Pesquisa e Consultoria Cientifica Ltda eBooks · doi:10.56041/9786599841804-2
The HIV Reservoir and Cure and Remission Strategies
Gandhi, R. T., Jülg, B. D., Jilg, N., Jakharia, N., & Talwani, R. (2021) · Oxford University Press eBooks · doi:10.1093/med/9780197576595.003.0026
AVELAR, I. D. S., & ALEXANDRINO, A. V. (2021) · Publicatio UEPG Ciencias Biologicas e da Saude · doi:10.5212/publ.biologicas.v.27.i2.0002
Chimeric antigen receptor engineered cells and their clinical application in infectious disease
Chen, Q., Bo, X., Hao, J., Wang, Z., & Li, B. (2022) · Clinical and Translational Discovery · doi:10.1002/ctd2.129
Centner, C. S. (2022) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/3863
Retroviruses: Reversing the dogma of life - A review
Shobha, P., Andrew, M., Shrina, P., Aayushi, P., Gregory, W., Kane, S., Lookfong, N. A., Abigayle, N., Xiuli, S., & Sairam, R. V. (2022) · Journal of Clinical Microbiology and Biochemical Technology · doi:10.17352/jcmbt.000051 · Cited by 1
CRISPR and gene editing in HIV therapy: A scoping review
Universidad de La Sabana, F. D. M., & Tuta-Quintero, E. (2023) · Gaceta Médica de Caracas · doi:10.47307/gmc.2023.131.1.18
Development of Medicinal Products Based on Gene-Editing Technology: Regulatory Practices
Pokrovsky, N. S., Vodyakova, M. A., Melnikova, E. V., & Меркулов, В. А. (2023) · The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products Regulatory Research and Medicine Evaluation · doi:10.30895/1991-2919-2023-481
Crispr/Cas: An Emerging Genome Editing Tool To Combat Viral Infections In Humans
(2022) · International Journal of Technology and Engineering Studies · doi:10.20469/ijtes.8.40003-1 · Cited by 1
CRISPR/Cas System: An Effective Tool Against Pathogenic Diseases
Aslam, S., Umair, A., Aslam, Z., Saleem, M., & Bashir, H. (2023) · Postępy Mikrobiologii - Advancements of Microbiology · doi:10.2478/am-2023-0009 · Cited by 1
“For this purpose, they targeted the NF-κB binding cassettes in TAR sequence of R region and LTR sequence of U3 region [31].”
InfluentialThe HIV Reservoir and Cure and Remission Strategies
Jülg, B. D., Gandhi, R. T., & Jilg, N. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780197679098.003.0019
HIV-1 mRNA Knockdown with CRISPR/Cas9 Enhances Neurocognitive FunctionPreprint
McLaurin, K. A., Li, H., Khalili, K., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3266933/v1
“…of single gRNA molecules to target the �anking HIV-1 long terminal repeat (LTR) sequences provided a fundamental proof-of-concept, whereby treatment cleaved viral DNA in vitro and inhibited viral gene expression (Ebina et al., 2013; Hu et al., 2014; Kaminski et al., 2016a; Yin et al., 2016).”
BackgroundAntiviral research and detecting viral nucleic acids based on the CRISPR-Cas technology
Li, P. (2023) · Theoretical and Natural Science · doi:10.54254/2753-8818/27/20240712
Genome Editing for Biotic Stress Resistance in Medicinal Plants
Insaf, M., Saddique, M. A. B., Sher, M. A., Khan, M. A., Usman, M. H., Karimi, S., Binyamin, R., & Khan, Z. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815136838123010014 · Cited by 1
Antiretroviral therapy and its cerebral vascular toxicity
Rudd, H., & Toborek, M. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99744-7.00030-4
Aplicaciones clínicas de la herramienta CRISPR-Cas
Vaglio-Cedeño, C., Rodriguez, E. J. R., & Morales, F. (2023) · Acta Médica Costarricense · doi:10.51481/amc.v65i3.1268 · Cited by 1
Mkhize, Z. (2023) · ResearchSpace (University of KwaZulu-Natal) · doi:10.29086/10413/23002
Tùng, B. T., Trang, V. T. T., & Anh, N. T. V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-16013-4.00004-x · Cited by 1
Host- and genomics-based antiviral approaches
Mostafa, A., Khalil, A. M., Hegazy, A., Mahmoud, S. H., & Martínez‐Sobrido, L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18866-4.00010-9
Bazazzadegan, N., Hasanzad, M., & Abedini, S. S. (2024) · Springer eBooks · doi:10.1007/978-981-97-4974-4_9 · Cited by 1
Zhang, C., Li, H., Bidasee, K. R., Gendelman, H. E., & Dash, P. K. (2024) · Springer eBooks · doi:10.1007/978-3-031-68237-7_55
Application of CRISPR/Cas9 based therapy in SCD, DMD and HIV
Shen, M. (2024) · Theoretical and Natural Science · doi:10.54254/2753-8818/2024.la18761
A növények antivirális RNS csendesítési mechanizmusainak molekuláris vizsgálata
Ludman, M. (2024) · Eötvös Loránd Tudományegyetem · doi:10.15476/elte.2024.045
The HIV Reservoir and Cure and Remission Strategies
Jülg, B. D., Gandhi, R. T., & Jilg, N. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197812631.003.0018
Khodadad, N., Fani, M., Khodadad, M., et al. (2025) · Journal of Current Biomedical Reports · doi:10.61882/jcbior.6.3.326
“The chimeric CRISPR/Cas9 system has been modified for use in the cells of eukaryotic organisms, leading to alterations in the genomes of various organisms, such as Drosophila, Zebrafish, Caenorhabditis elegans , yeast, plants, and even mammals [14,15,18].”
Mandal, S., Baloch, A. R., Yuan, X., Chen, J., Sarıbaş, A. S., Zhu, Y., Zhang, D., Jaijyan, D. K., Xu, J., Hossain, R. A., et al. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.102939 · Cited by 1
“The CRISPR/Cas9 excision was directed by dual sgRNAs targeting the LTR and structural region of the HIV-1 genome due to several advantages previously reported by our group [11,18,25 – 27] and others [13,14,17,24,87 – 91].”
RfxCas13d Mediates Broad-Spectrum Suppression of Highly Pathogenic Avian InfluenzaPreprint
Dhakal, S., Smith, A. J., Weiss, E., Islam, M. Z., Nazareth, L., LEE, T., Gough, T. J., Nair, K. K., Wilson, L. O. W., Wynne, J. W., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.18.712793
Elucidating the kinetics of CRISPR–SaCas9 action to obtain effective HIV DNA excision with two gRNAs
Yu, Z., Bao, Y., Alcalá-Lalinde, A., dos Ramos, Z. A., Koroglu, M., Berkhout, B., & Herrera-Carrillo, E. (2026) · Nucleic Acids Research · doi:10.1093/nar/gkag205
“While previous studies have demonstrated CRISPR –Cas-mediated HIV-1 excision, the reported excision efficiency is low and likely overestimated because of PCR-bias for amplification of shortened excision fragments [ 17 , 45 –47 ].”
Casado, L. S. (2015) · theses.fr (ABES) · doi:10.70675/4688548ezcd1bz4f6bz9c53z7adb5900fd6f
Synaptopathies auditives et vestibulaires : de la physiologie moléculaire à la thérapie génique
Calvet, C. (2020) · theses.fr (ABES) · doi:10.70675/8920e327zd8ffz457ez9711zcfc53af428dc
Effah, S. N., Barrera, S. C., Ortiz, N. U., Dampier, W., Nonnemacher, M. R., & Wigdahl, B. L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135905 · Cited by 1
“A study by Ebina et al. targeted the NF-kB and TAR sites of the U3 region and R region of HIV-1 LTR, respectively, in the HIV-1 latently infected Jurkat T cell line [205].”
Influentialdu Plessis, J., & Omar, A. (2026) · Cancer Medicine · doi:10.1002/cam4.72112 · Cited by 1
“At its simplest, CRISPR-Cas9 editing involves targeting a genomic locus with a guide RNA, generating a DNA break, and exploiting endogenous repair pathways to disrupt or modify gene sequence (Figure 2) [29–32].”
Triple-Target CRISPR Strategy to Block HIV Entry and Replication in Permissive Cells
Safaei, Z., Bellizzi, A., Liu, H., Huang, Y., Sariyer, I. K., & Khalili, K. (2026) · Human Gene Therapy · doi:10.1177/10430342261463565
HIV cure: from early therapies to cutting-edge strategies
Safaei, Z., & Khalili, K. (2026) · Journal of NeuroVirology · doi:10.1007/s13365-026-01343-5
“In 2013, Ebina and colleagues provided an early proof-of-concept by directing CRISPR/Cas9 to the HIV-1 long terminal repeat (LTR), demonstrating that sequence-specific genome editing could suppress proviral expression in infected cells (Ebina et al. 2013).”
Metadata
- Authors
- Ebina, H., Misawa, N., Kanemura, Y., & Koyanagi, Y.
- Affiliations
- Kyoto University (JP)
- Corresponding author
- Ebina, Hirotaka
- Venue
- Scientific Reports
- Published
- 2013-08-26
- Volume
- 3
- Issue
- 1
- Pages
- 2510-2510
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC3752613
- OpenAlex
- W1966452674
- Cited by
- 565
- References
- 28
- Citations by year
- 2026: 13 · 2025: 19 · 2024: 39 · 2023: 28 · 2022: 50 · 2021: 52 · 2020: 51 · 2019: 35 · 2018: 46 · 2017: 58 · 2016: 73 · 2015: 61 · 2014: 36 · 2013: 3
- FWCI
- 25.82
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/3.0/ (tdm)
- creativecommons.org/licenses/by/3.0/ (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion)
- Kyoto University Research Information Repository (Kyoto University) (submittedVersion, cc-by)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology (24115008)
- Japan Society for the Promotion of Science (24790438, 24390112)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- CRISPR/Cas9, HIV-1 provirus, latent HIV-1 reservoir, HIV-1 latency, HIV-1 cure, genome editing, T cells, HIV-1 reactivation
- MeSH terms
- HeLa Cells, Humans, HIV-1, HIV Long Terminal Repeat, Virus Latency, Gene Silencing, HEK293 Cells, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-27, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-27 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.